Ani pharmaceuticals announces fda approval and imminent launch of clorazepate dipotassium tablets usp

Baudette, minn.--(business wire)--ani pharmaceuticals, inc. (ani or the company) (nasdaq: anip) today announced that the company received u.s. food and drug administration (fda) approval for the abbreviated new drug application (anda) for clorazepate dipotassium tablets. ani's clorazepate dipotassium tablets are the generic version of the reference listed drug (rld) tranxene®. the current annual u.s. market for clorazepate dipotassium tablets is approximately $25.8 million, according to iqvia/i
ANIP Ratings Summary
ANIP Quant Ranking